Hanx Biopharmaceuticals-B (03378.HK) Controlling Shareholders Voluntarily Extend Lock-Up by 12 Months
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK) announced on June 24, 2026, that reference is made to the Company's prospectus dated December 15, 2025 and the Company's allotment results announcement dated December 22, 2025, which disclosed, among other things, that the shares held by all pre-IPO shareholders including the controlling shareholders of the Company, as well as cornerstone investors, were subject to lock-up periods. The lock-up period for the controlling shareholders and pre-IPO investors was to expire on December 22, 2026; the lock-up period for cornerstone investors was to expire on June 22, 2026.
Recently, the Company received notices from all controlling shareholders, whereby the controlling shareholders undertook not to reduce their respective holdings of the Company's shares in any manner during an extended lock-up period of 12 months from the expiry date of the original lock-up period. At the same time, the Company received notices from certain pre-IPO shareholders and cornerstone investors, whereby certain pre-IPO shareholders undertook not to reduce their respective holdings during an extended lock-up period of 6 months from the expiry date of the original lock-up period, and certain cornerstone investors undertook not to reduce their respective holdings during an extended lock-up period of 7 months from the expiry date of the original lock-up period.
Specific shareholding information and extended lock-up arrangements are as follows: Cai Zhang Biotech (Hangzhou) Co., Ltd. (holding 55,300,000 shares), Wuhan Hanstai Management Consulting Partnership (Limited Partnership) (holding 3,045,070 shares), and Hanx Biomedical (Hong Kong) Co., Ltd. (holding 17,793,640 shares) have all undertaken not to reduce their holdings from the expiry date of the original lock-up period to December 22, 2027 (inclusive); Beijing Longpan Biomedical Venture Investment Center (Limited Partnership) (holding 12,860,470 shares), Betta Pharmaceuticals Co., Ltd. (holding 6,430,230 shares), Hangzhou Taikun Equity Investment Fund Partnership (Limited Partnership) (holding 2,562,050 shares), Tibet Longpan SME Development Fund Equity Investment Partnership (Limited Partnership) (holding 1,195,620 shares), Hainan Yangzi Investment Co., Ltd. (holding 1,024,080 shares), Yangtze Investment (HK) Limited (holding 779,940 shares), and Lapam Capital HK Co., Limited (holding 596,040 shares) have all undertaken not to reduce their holdings from the expiry date of the original lock-up period to June 22, 2027 (inclusive); Chunlei Capital Limited (holding 125,000 shares) and Guotai Junan Securities Investment (Hong Kong) Limited (its ultimate client Kunyang, being Kunyang New Pattern No. 1 Private Securities Investment Fund) have undertaken not to reduce their holdings from the expiry date of the original lock-up period to January 22, 2027 (inclusive).
The Company believes that the extension of the lock-up period demonstrates the confidence of the aforementioned shareholders in the Company's future prospects, core technological strengths and long-term value. The aforementioned shareholders will also continue to review the Company's performance and may consider further extending the lock-up period based on the Company's business development.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
